Among 32 pharma and biotech companies surveyed, structure-based drug design is the most prevalent activity with the most players emphasizing the fragment-based variation.
Opportunities and Challenges Associated with Novel Companion Diagnostic Techn...L.E.K. Consulting
L.E.K. Managing Director Alex Vadas spoke at a BDA workshop on "How to Mature Emerging Technologies into Companion Diagnostics?" See his presentation here.
The Laboratory Analytical and Life Science Instrument Industries: Looking Ahe...Bill Kelly
We take a look at the market hotspots to watch in 2018 for the Laboratory Analytical and Life Science Instrument Industries by giving you an overview of the market by the numbers and highlight specific industries including spectroscopy, chromatography, diagnostics, and laboratory software.
ScienceCloud: Collaborative Workflows in Biologics R&DBIOVIA
The life sciences industry has undergone dramatic changes and effective global collaboration has become a key success factor in this new age. BIOVIA is providing a hosted and comprehensive solution stack for externalized, collaborative research for pharma/biotech and CROs to address these new challenges. Recently we added the support for biologics data management and IP capture. In this talk we will present collaborative and comprehensive capabilities in antibody characterization and development: capabilities to analyze, annotate and predict developability as part of a framework that facilitates secure data sharing and collaboration.
This Slideshare discusses the current state, technical and workflow challenges, and the future state of Patient Generated Health Data. Learn more: https://accntu.re/2KeGkZ6
Opportunities and Challenges Associated with Novel Companion Diagnostic Techn...L.E.K. Consulting
L.E.K. Managing Director Alex Vadas spoke at a BDA workshop on "How to Mature Emerging Technologies into Companion Diagnostics?" See his presentation here.
The Laboratory Analytical and Life Science Instrument Industries: Looking Ahe...Bill Kelly
We take a look at the market hotspots to watch in 2018 for the Laboratory Analytical and Life Science Instrument Industries by giving you an overview of the market by the numbers and highlight specific industries including spectroscopy, chromatography, diagnostics, and laboratory software.
ScienceCloud: Collaborative Workflows in Biologics R&DBIOVIA
The life sciences industry has undergone dramatic changes and effective global collaboration has become a key success factor in this new age. BIOVIA is providing a hosted and comprehensive solution stack for externalized, collaborative research for pharma/biotech and CROs to address these new challenges. Recently we added the support for biologics data management and IP capture. In this talk we will present collaborative and comprehensive capabilities in antibody characterization and development: capabilities to analyze, annotate and predict developability as part of a framework that facilitates secure data sharing and collaboration.
This Slideshare discusses the current state, technical and workflow challenges, and the future state of Patient Generated Health Data. Learn more: https://accntu.re/2KeGkZ6
ValGenesis Case Study With Scinopharm -Paperless Validation Software Solution ValGenesis
ValGenesis delivered a validated and qualified system in six weeks – the rapid implementation we needed. The system has been stable from the start, with little need for customer support calls, allowing us to focus on training and bringing on new users every week.”
— Steve Johnson, Director, Operations
Injectable Facility
ScinoPharm Taiwan, Ltd.
PAREXEL's Matt Neal joins experts from Microsoft and Allergan to discuss how innovations in technology can help patients by reducing the time and expense of bringing life-saving treatments to market.
For Life Sciences, the Future of Master Data Management is in the CloudCognizant
Cloud-based MDM is cost-effective and easily implemented; it is scalable, robust and mature; and it has the flexibility required to enable and support the evolving transformation of life sciences commercial operations.
Medisafe_What's Next in RWE_mHealth IsraelLevi Shapiro
Presentation by Medisafe CEO, Omri Shor, Oct 19, 2021, for the mHealth Israel community.
- Medisafe’s Patient Engagement Platform
- Real World Evidence: Economic Impact for Pharma
- Connecting Pharma to patients
- Case Study: Supporting Patients through Digital Platform
-
DayOne Experts - Next generation clinical trialsDayOne
Event introduction slides by Thomas Brenzikofer.
Read the event report here:https://www.baselarea.swiss/baselarea-swiss/channels/innovation-report/2019/06/on-the-verge-of-being-born-next-generation-clinical-trials.html
Tomasz Sablinski, Founder and CEO of Transparency Life Sciences raised the crunch question of the evening: Which industry is lagging behind the most in terms of digitization? Right, it is the healthcare industry! But who would have expected the usual lamentation of why this is the case; blaming regulatory constraints, scarce innovation culture, or unachievable technology barriers proved wrong. The appetite for change and finding new ways of doing things was too strong among Basel’s Healthcare innovators at the DayOne Expert Session on “Next Generation Digital Trials”.
The idea of the event was to present a holistic view of the current standing in the digitizing clinical trials.
Patient Centricity: EHR Pillars to Patient CentricityDayOne
AT the DayOne Experts - Next Generation Clinical Trials, Randy Ramin-Wright from Clinerion demonstrated how patient recruitment works in the digital age.
Janice Haigh, PAREXEL's Worldwide Head of Pricing & Market Access, on how clinical research organizations simplify the journey from strategy to results.
Next Generation Digital Trials - Introduction to a changing landscape DayOne
Data Analytics Perspective: Stijn Rogiers, SAS and explained why his company is prepared – having being around for decades as the “Rolls Royce” software provider in the fields of data science and analytics.
Transforming Pharmacovigilance Workflows with AI & Automation Perficient, Inc.
Medical information call centers have an opportunity to transform the way they capture, code, and analyze adverse events (AEs) and product quality complaints (PQCs) with artificial intelligence (AI) and automation.
The use of such innovative technology improves data quality and consistency, compliance, and operational efficiency. It helps reduce the frequency of your pharmacovigilance (PV) operations resources going home, saying, “I have more to do at the end of the day than I did when I started."
Our one-hour, on-demand webinar shows you how you can use AI and automation to turbo-charge your end-to-end PV system. Use cases and demonstrations will include:
Analyzing safety data
Auto-coding verbatim terms to official medical dictionary terms
Auto-creating an AE case in your database
Converting speech to text
Tomasz Sablinski from Transparency Life Sciences showed at the DayOne Expert event - Next Generation Clinical Trials ways to virtualize clinical trials or parts of them.
At the DayOne Experts even - Next Generation Clinical Trials, Lars G. Hemkens from University Hospital Basel shared his experience on how integrating data, that has been collected on a routine basis, into clinical trials will make a difference.
Practical Drug Discovery using Explainable Artificial IntelligenceAl Dossetter
How to build AI systems to enable the drug hunting medicinal chemist in their day-to-day work. Levels are AI are described and the meaning and context Explainable AI to medicinal chemists. Six medicinal chemist projects are described, as well as Matched Molecular Pair Analysis (MMPA), Machine Learning and Permutative MMPA. In each case how a system can be built to drill back to chemical sub-structures so effective decisions can be made.
MedChemica BigData What Is That All About?Al Dossetter
A light look at the world of BigData for the lay person - a look at a couple of examples and what we do in MedChemica to speed up drug discovery. First presented at Macclesfield SciBar, and then Knutsford SciBar.
Accelerating multiple medicinal chemistry projects using Artificial Intellige...Al Dossetter
The technical methods and results of Matched Molecular Pair Analysis (MMPA) applied from a small, individual assay scale through large pharma scale, to multiple pharma data sharing scale have been published and reviewed. The drive behind these efforts has been to derive a medicinal chemistry knowledge base (i.e. definitive textbook) that can be applied to drug discovery projects. The aim is to greatly decrease the time in lead identification and optimization by the synthesis of fewer compounds. Such a system suggests compound designs to expert chemists to triage; such a process is Artificial Intelligence (AI). Given this context, how does this work on projects? How do the chemists make decisions? What are the results? The talk will answer these questions through project examples where MMPA has been applied and how this led to drug candidates. The projects disclosed are from multiple organisations and describe Cathepsin K inhibitors, Glucokinase Inhibitors, 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors (11β-HSD1), Ghrelin inverse antagonists and Tubulin Polymerization inhibitors. An overview of MMPA will be presented and each project will be briefly described with a focus on how the chemists used MMPA to understand SAR and design compounds. The impact of project progress to CD will be quantified.
Educating the Next Generation Pharmacist for Industry. The Panjab University ...Ajaz Hussain
The Panjab University Pharmaceutical Science Oration 2014: Educating the Next Generation Pharmacist for Industry.
“The dream begins with a teacher who believes in you, who tugs and pushes and leads you to the next plateau, sometimes poking you with a sharp stick called ‘truth’.“
Plato, the Republic
What are the most influential ideas, concepts, and developments introduced by ‘pharmaceutical scientists’ over the last 50 years?
How have these ideas/concepts introduced into practice?
How can we improve?
Young pharmaceutical scientists are and can get involved in all aspects of new drug discovery and development. They have to be appropriately qualified, trained and experienced though,
ValGenesis Case Study With Scinopharm -Paperless Validation Software Solution ValGenesis
ValGenesis delivered a validated and qualified system in six weeks – the rapid implementation we needed. The system has been stable from the start, with little need for customer support calls, allowing us to focus on training and bringing on new users every week.”
— Steve Johnson, Director, Operations
Injectable Facility
ScinoPharm Taiwan, Ltd.
PAREXEL's Matt Neal joins experts from Microsoft and Allergan to discuss how innovations in technology can help patients by reducing the time and expense of bringing life-saving treatments to market.
For Life Sciences, the Future of Master Data Management is in the CloudCognizant
Cloud-based MDM is cost-effective and easily implemented; it is scalable, robust and mature; and it has the flexibility required to enable and support the evolving transformation of life sciences commercial operations.
Medisafe_What's Next in RWE_mHealth IsraelLevi Shapiro
Presentation by Medisafe CEO, Omri Shor, Oct 19, 2021, for the mHealth Israel community.
- Medisafe’s Patient Engagement Platform
- Real World Evidence: Economic Impact for Pharma
- Connecting Pharma to patients
- Case Study: Supporting Patients through Digital Platform
-
DayOne Experts - Next generation clinical trialsDayOne
Event introduction slides by Thomas Brenzikofer.
Read the event report here:https://www.baselarea.swiss/baselarea-swiss/channels/innovation-report/2019/06/on-the-verge-of-being-born-next-generation-clinical-trials.html
Tomasz Sablinski, Founder and CEO of Transparency Life Sciences raised the crunch question of the evening: Which industry is lagging behind the most in terms of digitization? Right, it is the healthcare industry! But who would have expected the usual lamentation of why this is the case; blaming regulatory constraints, scarce innovation culture, or unachievable technology barriers proved wrong. The appetite for change and finding new ways of doing things was too strong among Basel’s Healthcare innovators at the DayOne Expert Session on “Next Generation Digital Trials”.
The idea of the event was to present a holistic view of the current standing in the digitizing clinical trials.
Patient Centricity: EHR Pillars to Patient CentricityDayOne
AT the DayOne Experts - Next Generation Clinical Trials, Randy Ramin-Wright from Clinerion demonstrated how patient recruitment works in the digital age.
Janice Haigh, PAREXEL's Worldwide Head of Pricing & Market Access, on how clinical research organizations simplify the journey from strategy to results.
Next Generation Digital Trials - Introduction to a changing landscape DayOne
Data Analytics Perspective: Stijn Rogiers, SAS and explained why his company is prepared – having being around for decades as the “Rolls Royce” software provider in the fields of data science and analytics.
Transforming Pharmacovigilance Workflows with AI & Automation Perficient, Inc.
Medical information call centers have an opportunity to transform the way they capture, code, and analyze adverse events (AEs) and product quality complaints (PQCs) with artificial intelligence (AI) and automation.
The use of such innovative technology improves data quality and consistency, compliance, and operational efficiency. It helps reduce the frequency of your pharmacovigilance (PV) operations resources going home, saying, “I have more to do at the end of the day than I did when I started."
Our one-hour, on-demand webinar shows you how you can use AI and automation to turbo-charge your end-to-end PV system. Use cases and demonstrations will include:
Analyzing safety data
Auto-coding verbatim terms to official medical dictionary terms
Auto-creating an AE case in your database
Converting speech to text
Tomasz Sablinski from Transparency Life Sciences showed at the DayOne Expert event - Next Generation Clinical Trials ways to virtualize clinical trials or parts of them.
At the DayOne Experts even - Next Generation Clinical Trials, Lars G. Hemkens from University Hospital Basel shared his experience on how integrating data, that has been collected on a routine basis, into clinical trials will make a difference.
Practical Drug Discovery using Explainable Artificial IntelligenceAl Dossetter
How to build AI systems to enable the drug hunting medicinal chemist in their day-to-day work. Levels are AI are described and the meaning and context Explainable AI to medicinal chemists. Six medicinal chemist projects are described, as well as Matched Molecular Pair Analysis (MMPA), Machine Learning and Permutative MMPA. In each case how a system can be built to drill back to chemical sub-structures so effective decisions can be made.
MedChemica BigData What Is That All About?Al Dossetter
A light look at the world of BigData for the lay person - a look at a couple of examples and what we do in MedChemica to speed up drug discovery. First presented at Macclesfield SciBar, and then Knutsford SciBar.
Accelerating multiple medicinal chemistry projects using Artificial Intellige...Al Dossetter
The technical methods and results of Matched Molecular Pair Analysis (MMPA) applied from a small, individual assay scale through large pharma scale, to multiple pharma data sharing scale have been published and reviewed. The drive behind these efforts has been to derive a medicinal chemistry knowledge base (i.e. definitive textbook) that can be applied to drug discovery projects. The aim is to greatly decrease the time in lead identification and optimization by the synthesis of fewer compounds. Such a system suggests compound designs to expert chemists to triage; such a process is Artificial Intelligence (AI). Given this context, how does this work on projects? How do the chemists make decisions? What are the results? The talk will answer these questions through project examples where MMPA has been applied and how this led to drug candidates. The projects disclosed are from multiple organisations and describe Cathepsin K inhibitors, Glucokinase Inhibitors, 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors (11β-HSD1), Ghrelin inverse antagonists and Tubulin Polymerization inhibitors. An overview of MMPA will be presented and each project will be briefly described with a focus on how the chemists used MMPA to understand SAR and design compounds. The impact of project progress to CD will be quantified.
Educating the Next Generation Pharmacist for Industry. The Panjab University ...Ajaz Hussain
The Panjab University Pharmaceutical Science Oration 2014: Educating the Next Generation Pharmacist for Industry.
“The dream begins with a teacher who believes in you, who tugs and pushes and leads you to the next plateau, sometimes poking you with a sharp stick called ‘truth’.“
Plato, the Republic
What are the most influential ideas, concepts, and developments introduced by ‘pharmaceutical scientists’ over the last 50 years?
How have these ideas/concepts introduced into practice?
How can we improve?
Young pharmaceutical scientists are and can get involved in all aspects of new drug discovery and development. They have to be appropriately qualified, trained and experienced though,
Discovery of Drug and Introduction to Clinical Trial_Katalyst HLSKatalyst HLS
Introduction to Discovery of Drug and Introduction to Clinical Trials in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
The Survivor community can learn more about the state of the art in new tests available in cancer centres, which pinpoint specific types of tumours that will respond best to treatments.
Generic non-biological complex drugs DIA CMC Workshop 2017Ajaz Hussain
#DIACMC17
Assigned title for the talk by the organizers: “The need of conducting clinical study for assuring safety and efficacy, as well as a lack of immunogenicity for generic NBCDs”
SUMMARY
Integrated analytical, product and process development to reduce uncertainty in ‘pharmaceutical equivalence’ is the foundation on which confidence in generic drugs rests
Need to leverage the context: RLD “Prescribe-ability” and lot-lot “Switchability” is acceptable
The “sameness” mindset (as opposed to an “equivalence” mindset) poses challenges to evidence ‘synthesis” (not “piece meal” check the box ) in ANDA submissions
Integrated evidence must a priori account for posed/anticipated “legal challenges” intrinsic to the US system
Clinical assessment of Therapeutic Equivalence of generic product intended (i.e., designed) to be equivalent to RLD should only be needed in rare circumstances
When there is a need to provide assurance to non-scientists stakeholders
Currently the FDA’s GADUFA Research and efforts by many in the sector are predominantly focused on developing a “test of bioequivalence”
For most complex products such a test, in and of itself, may be insufficient to ensure therapeutic equivalence over generic product life-cycle
Pharmaceutical chemistry - DU SEC ppt projectrahultest01234
Drug discovery, design and development: Sources of drugs: biological, marine, minerals and plant tissue
culture, physio-chemical aspects (optical, geometric and bioisosterism) of drug molecules and biological
action
Pharmaceutical industry – change in discovery and developmentBhaswat Chakraborty
Drug discovery and development of yester years
Drug discovery and development now
Preclinical
Drug
Organization
Clinical
IT & Data management
Approval
Postapproval
Ayurveda shows a way forward to drug discoverysaumyagulati4
drug discovery in Ayurveda.
Is there is a need for Stepwise drug discovery in Ayurveda?
i:e from in-vitro to Clinical.
or Clinical to laboratory research in Ayurveda.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
This expanding series attracts the leading authorities worldwide working in companion diagnostics, biomarkers, immuno-oncology, liquid biopsies, AI and other facets of precision medicine. It has been praised for its stimulating, interactive and engaging environment where it brings together a multi-disciplined community of researchers, leaders and innovators whose aim is to develop groundbreaking and impactful treatments for patients.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
Similar to Structure-Based Drug Design Facts & Figures Infographic (20)
CHI's Next Generation Dx Summit 2022 | August 22-24, 2022 | Washington, D.C.James Prudhomme
Advancing Diagnostics Together
We are proud to host Cambridge Healthtech Institute's Fourteenth Annual Next Generation Dx Summit which will take place in-person at the Grand Hyatt Washington, D.C. on August 22-24. The Next Generation Dx Summit is the nexus for key opinion leaders across the world to share recent progress in diagnostic advancement and technology innovation. The event provides a valuable window on how point-of-care, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care. Now in its fourteenth year, the Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important topics for the industry.
CHI's Targeting Stromal Cells in Cancer and Inflammatory Diseases Conference ...James Prudhomme
This virtual meeting will highlight cutting-edge science and provide insight into recent developments towards therapeutic stromal cell targeting in cancer and chronic inflammatory diseases. View full details and register: https://www.healthtech.com/stroma-conference
CHI's Next Generation Dx Summit | August 25-27, 2020 | Washington, DCJames Prudhomme
Next Generation Dx Summit brings together more than 800 international diagnostic professionals working in the field and offers unparalleled insight from the comprehensive programming and networking with key opinion leaders in the industry. The event is unique in the marketplace. This year the coverage spans cell- and cell-free biopsies, commercialization, reimbursement, biomarkers and companion diagnostics for immunotherapy, point-of-care testing, infectious disease, microfluidics and precision medicine. Now in its twelfth year, Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.
CHI's 10th Annual Next Generation Dx Summit, August 20-24, 2018, Washington, DCJames Prudhomme
Next Generation Dx Summit has grown to more than 1,000 international diagnostic professionals working in the field and offers unparalleled insight from the comprehensive programming and networking with key opinion leaders in the industry. The event is unique in the marketplace. This year the coverage spans cell- and cell-free biopsies, commercialization, reimbursement, biomarkers and companion diagnostics for immunotherapy, point-of-care testing, infectious disease, microfluidics and precision medicine. Now in its tenth year, Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.
CHI's Bioassays for Immuno-Oncology Symposium, Oct. 23, 2017 in Washington, DCJames Prudhomme
Biological assays demonstrating drug characteristics such as potency, mechanism-of-action, and stability, are one of the most critical components of an FDA biologic submission. However, with more complex mechanisms-of-action, immunotherapies add a layer of difficulty to bioassay selection and development. At Cambridge Healthtech Institute's Inaugural Bioassays for Immuno-Oncology symposium, experts in bioassays for immuno-oncology therapies will discuss selection, development, and standards for bioassays and immunoassays. Special attention will be given to understanding the mechanism-of-action for immunotherapies, whether they be antibody- or cell-based. Overall, this one-day immersive symposium will outline a product life cycle approach for developing and implementing biological assays from preclinical studies to clinical development. This symposium is part of the Immunogenicity & Bioassay Summit.
Immuno-Oncology Course, organized by Healthcare Education ServicesJames Prudhomme
The Immuno-Oncology one-day course provides an overview of the rapidly evolving subject of immune-oncology. Delegates are offered a thorough understanding of the basics of tumor immunology as well as the essentials of immunotherapy and its application in cancer medicine. Examples of both how biologics work in the practice of oncology and of the challenges presented are demonstrated.
The program has been developed specifically to support the needs of the pharmaceutical, biotechnology and medical technology industry personnel. It is ideal for individuals with little understanding of the immunotherapy of cancer and those with an existing basic knowledge. Detailed presentations and discussion with Healthcare’s experienced and knowledgeable faculty enable thorough insight to this important subject area.
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...James Prudhomme
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed.
Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer.
Hematologic Cancers - An Introduction Course, organized by Healthcare Educati...James Prudhomme
This course reviews the hematological system and provides an overview on the spectrum of hematologic cancers. The expert teaching team, comprising currently practising physicians, guides course attendees through the pathophysiology of Hematologic Cancers - An Introduction such as leukemias, lymphomas and myeloma. Common treatments and management of these malignancies are discussed as well as the challenges these treatments present to patients. The issues and complications of bone marrow and stem cell transplant are also reviewed. Case studies and open discussion form an integral part of the program.
Overcome Operational Challenges in Biomarker-driven Clinical TrialsJames Prudhomme
Cambridge Healthtech Institute offers two back-to-back symposia on the operational aspects of precision medicine trials and the improvement of infrastructure to better support those trials. The 2nd Annual Managing Precision Medicine Trials Symposium (January 24-25, 2017) focuses on strategizing design for biomarker driven trials and novel clinical trial design. The Inaugural Sample, Lab and Diagnostics Services in Clinical Trials Symposium (January 25-26, 2017) focuses on clinical sample management and sourcing and diagnostics services.
Cambridge Healthtech Institute (CHI) is pleased to announce the Third Annual FAST: Functional Analysis and Screening Technologies Congress. Now in its third year, the FAST Congress brings you the latest technologies and research in cellular screening.
The Third Annual Phenotypic Drug Discovery meeting will return with new updates and case studies in phenotypic screening, high-content analysis, physiologically-relevant cellular models, chemical genomics and chemical proteomics. The rapidly evolving area of 3D cellular models will be addressed by two back-to-back meetings, with the Inaugural 3D Cell Culture: Organoid, Spheroid, and Organ-on-a-Chip Models meeting focusing on the new predictive cellular models for drug discovery and toxicity assessment. It will review the use of primary and stem cells, complex co-culture cell models, tumor spheroid models, novel organ-on-a-chip models for efficacy and safety screening, functional analysis, and compound profiling. The Third Annual Screening and Functional Analysis of 3D Models meeting will follow with case studies of phenotypic and high-content screening of complex 3D cellular systems for compound and target selection.
The 2014 Congress attracted more than 250 senior delegates, representing over 160 companies from 20 countries. With half of the attendees from big pharma and biotech and a third from academia and government, the FAST Congress offers exclusive networking opportunities with diverse international attendance. Please join our focused Screening event and learn from 60+ scientific presentations, an assortment of educational courses, 20+ exhibitors and your fellow expert delegates. We look forward to seeing you at the event.
Next Generation Dx Summit 2015 - Moving Assays to the ClinicJames Prudhomme
The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
Cambridge Healthtech Institute's fourth annual Clinical Trial Oversight Summit will feature four co-located conferences covering best practices and recent trends relevant to clinical research monitoring, auditing, clinical quality assurance, site management, and vendor oversight. This four-day summit will include presentations from experts, case studies, interactive breakout discussion groups, workshops, and networking opportunities. Themes throughout will include risk-based approaches to clinical trial management, implementing quality systems-based approaches to GCP compliance, ensuring reliable study data, responding to the evolving regulatory landscape, and preparing sites and clinical research partners for inspection-readiness.
Call for Posters: Functional Analysis & Screening TechnologiesJames Prudhomme
Cambridge Healthtech Institute (CHI) is accepting scientific posters from industry & academic researchers on improving the screening success of rate drugs using 3D models & phenotypic screening for display at it's second annual "FAST: Functional Analysis & Screening Technologies Congress" to be held on November 17-19, 2014. www.FASTCongress.com
Join us in Boston this coming Fall to attend Cambridge Healthtech Institute's (CHI) 2nd Annual FAST: Functional Analysis & Screening Technologies Congress on November 17-19, 2014 and meet with a community of 250+ biologists, screening managers, assay developers, engineers and pharmacologists dedicated to improving in vitro cell models and phenotypic screening to advance drug discovery and development at 6 conferences: Phenotypic Drug Discovery (Part I & II), Engineering Functional 3D Models, Screening and Functional Analysis of 3D Models, Organotypic Culture Models for Toxicology and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Delegates have the opportunity to share insights in interactive panel discussions and connect during networking breaks. View innovative technologies and scientific research revolutionizing early-stage drug discovery in the exhibit/poster hall.
Short Courses at CHI's Immunogenicity and Bioassay Summit 2014James Prudhomme
Cambridge Healthtech Institute (CHI) will once again offer comprehensive training at the Sixth Annual Immunogenicity and Bioassay Summit 2014. The following courses are led by well-respected professionals in the pharmaceutical industry who have much experience in helping investigators overcome their difficulties with these challenging assays and with risk assessment. Delegates will enjoy an intimate setting with their peers and instructors and have the opportunity to ask questions and exchange experiences.
Make Plans to Attend the Number 1 Immunogenicity and Bioassay Event Bringing Together Industry,
Academia and Regulatory Authorities. Featuring 8 FDA Presenters!
Course: Development of High-Dose Biologics Dosage FormsJames Prudhomme
Course: Development of High Dose Biologics Dosage Forms will be held on May 6, 2014 in Boston, MA - part of the Biologics Formulation & Delivery Summit.
Course: Challenges and Opportunities in Protein and Peptide Drug DeliveryJames Prudhomme
When: May 4, 2014
Where: Seaport World Trade Center, Boston, MA
Proteins and peptides represent a significant segment of the therapeutics spectrum with many promising candidates under early development or in late-stage clinical trials. Several of these molecules are poised to make a substantial impact, especially in the under-represented or unrepresented categories such as neurological disorders and neurodegenerative diseases. A key challenge to be overcome with protein and peptide based biologics, however, is their effective delivery to the target site while achieving the optimum balance of stability, safety, bioavailability, and patient compliance. This short course will provide a broad overview of the opportunities and challenges in the development of the next generation of protein and peptide therapeutic delivery systems.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Evaluation of antidepressant activity of clitoris ternatea in animals
Structure-Based Drug Design Facts & Figures Infographic
1. May 21 - 22, 2014 | Westin Boston Waterfront | Boston, MA
Fourteenth Annual
Structure-Based Drug Design
Using Structure and Rational Design to Accelerate Discovery
WHAT’S NEW
THIS YEAR:
• Coverage of novel targets and compounds
including macrocycles, epigenetic targets, and
BACE inhibitors
• Case studies and experimental follow up - see
how Constellation, Heptares, AstraZeneca, and
others are leading the SBDD charge
• Expanded sessions on GPCR design and
drug discovery
• Showcase of different approaches for working
with the similar targets
CAMBRIDGE HEALTHTECH INSTITUTE
250 First Avenue | Suite 300
Needham, MA 02494
PRSRT STD
US POSTAGE PAID
PERMIT NO. 6
HUDSON, MA
Fourteenth Annual
Structure-Based Drug Design
Using Structure and Rational Design to Accelerate Discovery
Hear case studies from:
• Arena Pharmaceuticals
• Astex
• AstraZeneca
• Bristol-Myers Squibb
• Carmolex
• Carmot Therapeutics
• Constellation Pharmaceuticals
• Genentech
• Heptares Therapeutics UK
• Merck
• Novartis
• Structural Genomics Consortium
• Takeda
• Vernalis, Ltd.
Drug Discovery
FACTS & FIGURES
FACT: Among 32 pharma and biotech
companies surveyed, structure-based
drug design is the most prevalent activity
with the most players emphasizing the
fragment-based variation.
2. Current Drug
Target Breakdown
Miscellaneous 2%
DNA 1%
Integrins 1%
Other Receptors 4%
Enzymes 47%
Nuclear Hormone
Receptors and
Transporters 8%
Ion Channels
7%
GPCRs 30%
FACT:
CONSIDER THIS
cost of bringing a
FACT: The average market is $1.3 billion
new drug to
FACT:
Fewer than 1 in 10
medicines that start
being tested in human
clinical trials will succeed
In 2012 the FDA approved
39 new drugs
FACT: The pharmaceutical market will reach nearly
$
1,200,000,000,000
USD by 2016
How will CHI’s 14th Annual
Structure-Based Drug Design
conference help to advance the drug discovery field?
By addressing topics that matter:
25%
GPCRs
By bringing together industry leaders:
Attendee
Profile
Executive 11%
Title
Director 12%
Manager 8%
Professor 12%
Scientist/Technologist 46%
Sales & Marketing 6%
50%
New techniques
and strategies
Other 5%
Computational Chemistry 15%
Function
Medicinal Chemistry 17%
Drug Discovery 13%
45%
Novel targets and
compounds
Discovery Technologies 6%
Structural Biology 9%
Structural Chemistry 13%
Biochemistry 11%
Keynote Speaker
Chas Bountra, Ph.D., Professor, Translational
Medicine, Department of Clinical Medicine;
Associate Head, Medical Sciences; Chief Scientist,
Structural Genomics Consortium, University of Oxford
Molecular Modeling 5%
Other 11%
Academic 24%
Biotech 41%
Government/
Research Institutions
Register and View Full Details:
healthtech.com/structure-based-drug-design
Register by February 28 and Save up to $400!
Mention keycode “INW” when registering
3%
Pharmaceutical 32%
USA 60%
Europe 25%
Asia 10%
ROW
Sources: Forbes, Insight Pharma Reports: Medicinal Chemistry, FDA.gov
Company Type
5%
Region
